Collaborators

Continuing to Build Our Offerings
In order to continuously develop and enhance our biocatalysis offering we collaborate with universities and specialist companies. Present collaborations include:

Professor Nick Turner, University of Edinburgh, UK
Professor J M Woodley, University College London, UK
Professor Jenny Littlechild, University of Exeter, UK
Dr. John Archer, University of Cambridge, UK

Diversa

U.K. Centre of Excellence in Biocatalysis, Biotransformations and Biocatalytic Manufacture (CoEBio3) - Dowpharma is one of the affiliate companies for the new CoEBio3. The Centre will comprise 60-80 researchers engaged in the use of natural catalysts (enzymes) for the preparation of high-value speciality chemicals, including pharmaceuticals and their intermediates. The overall objective of the centre is to rapidly expand the use of biocatalysis in synthetic organic chemistry.

Aquapharm Bio-Discovery Ltd - Dowpharma have recently entered into a collaboration with Aquapharm to investigate their marine bio-organisms as sources of novel biocatalysts. The company specifically specialises in the discovery and development of novel bio-active natural products from the isolation & culture of new marine microbes from the diverse UK coast line & beyond.

Through such collaborations, Dowpharma^SM remains on the cutting edge of biotransformation technology while enabling our partners to access the benefits of a global company infrastructure.

^SMService mark of The Dow Chemical Company


Capabilities and Services Biocatalysis Biocatalysis Capability Collaborators Enzyme Classes Chemocatalysis Asymmetric Hydrogenation Hydroformylation Trost Allylic Alkylation Complex Synthesis Products Offered Process Development Customer Needs Development Timeline Emerging Pharma Catalyst/Ligand Availability Unnatural Fmoc Amino Acids Unnatural Boc Amino Acids 2-Alkyl Succinates Amines Alcohols Functionalized Cyclopentanes Scaffolds Facilities Literature and Resources Asymmetric Hydrogenation Dowpharma Scientific Publications Hydroformylation Trost Allylic Alkylation Complex Synthesis Biocatalysis Process Development General Publications News Center Source: Aquapharm Bio-Discovery Ltd Enters a Collaboration Deal with Dowpharma<sup>SM</sup> Contract Manufacturing Services. Dowpharma Relaunches Web Site, Will Make Donation to UNICEF Dow Expands Presence in Pharmaceutical Market, Uniting Existing Offers Under Dowpharma Portfolio Dowpharma Announces New Capabilities in Asymmetric Hydroformylation for Pharmaceutical Applications License of JST Catalyst Technology Expands Dowpharma’s Chiral Commercial Production Capabilities Dowpharma Signs Agreement with Japanese Distributor to Market Pharmaceutical Services in Japan Events Calendar Contact Us	Collaborators Continuing to Build Our Offerings In order to continuously develop and enhance our biocatalysis offering we collaborate with universities and specialist companies. Present collaborations include: Professor Nick Turner, University of Edinburgh, UK Professor J M Woodley, University College London, UK Professor Jenny Littlechild, University of Exeter, UK Dr. John Archer, University of Cambridge, UK Diversa U.K. Centre of Excellence in Biocatalysis, Biotransformations and Biocatalytic Manufacture (CoEBio3) - Dowpharma is one of the affiliate companies for the new CoEBio3. The Centre will comprise 60-80 researchers engaged in the use of natural catalysts (enzymes) for the preparation of high-value speciality chemicals, including pharmaceuticals and their intermediates. The overall objective of the centre is to rapidly expand the use of biocatalysis in synthetic organic chemistry. Aquapharm Bio-Discovery Ltd - Dowpharma have recently entered into a collaboration with Aquapharm to investigate their marine bio-organisms as sources of novel biocatalysts. The company specifically specialises in the discovery and development of novel bio-active natural products from the isolation & culture of new marine microbes from the diverse UK coast line & beyond. Through such collaborations, Dowpharma^SM remains on the cutting edge of biotransformation technology while enabling our partners to access the benefits of a global company infrastructure. ^SMService mark of The Dow Chemical Company
	Small Molecules Dow Home Privacy Statement Internet Disclaimer Accessibility Statement Site Map Copyright © The Dow Chemical Company (1995-2008). All Rights Reserved.